Abstract：Objective: To detect the expression of mismatch repair proteins(MLH1, MSH2, MSH6 and PMS2)in the colorectal cancer and disscus the correlation between the clinicopathological characteristics and MMR protein. Methods: EnVision immunohistochemical method was used to detect the expression of MMR protein, and then analyze the relationship between the expression of mismatch repair protein of CRC patients and pathology features from 242 cases of colorectal cancer. Results: ①In 242 cases of colorectal cancer patients, total expression deletion rate was 14.04%, the expression deletion rate was of MLH1, hMLH2, hMSH6 and hPMS2 protein was respectively 10.03% (25/242), 1.2% (3/242), 1.2% (3/242) and 11.16% (27/242). hMLH1 and hPMS2 co-expression deletion rate was 9.50%(23/242), hMSH2 and hMSH6 co-expression deletion rate was 0.83% (2/242). ②All of MMR protein expression deletion was uncorrelated with sexuality, age, lymphatic metastasis in CRC (p＞0.05), the expression of hMLH1 protein was related to the differentiation degree of CRC (p＜0.05), the expression of hPMS2 protein was related to the location, size and differentiation degree of tumor (p＜0.05). Conclusion: The location, size and differentiation of tumors affect the expression of mismatch repair proteins hMLH1 and hPMS2 in CCR. The co-expression of hMLH1 and hPMS2, hMSH2 and hMSH6 is more common, and the deletion of hMLH1 and hPMS2 is more common.
[1] Rebecca Siegel,Jiemin Ma,Zhaohui Zou,et al. Cancer statistics, 2014[J].CA Cancer Clin,2014,64(1):9~29. [2] Delahunty R, Mcmurrick P, Carne P, et al. Screening for mismatch repair deficiency in colorectal cancer[J].Asia-Pacific Clinical Oncol, 2015, 11(S3): 52. [3] 李悠然,谷云飞.林奇综合征临床诊治研究进展[J].重庆医学,2016,45(14):1997~1999. [4] Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer[J].Cancer, 1993, 72(12):3641~3647. [5] 晋龙,眭玉霞,王丽萍,等.结直肠癌错配修复蛋白MLH1、MSH2、MSH6及PMS2表达与临床病理特征的关系[J].诊断病理学杂志,2017(11):813~817. [6] Gorman J, Greene E C. Target search dynamics during post-replicative mismatch repair[J].Cell Cycle, 2013, 12(4):537~538. [7] National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:Colon cancer((ersion1.2017)[EB/OL].http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. [8] Vindigni SM, Kaz AM. Universal screening of colorectal cancers for lynch syndrome: challenges and opportunities[J].Dig Dis Sci, 2016, 61(4):969~976. [9] Ye J X, Liu Y, Qin Y, et al. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients[J].World Gastroenterol, 2015, 21(5):1595~1605. [10] Edelbrock M A, Kaliyaperumal S, Williams K J. Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities[J].Mutat Res, 2013, 743(3):53~66. [11] Van Der Klift HM,Mensenkamp AR,Drost M,et al.Comprehensive mutation analysis of PMS2 in a large cohort of probands suspected of lynch syndrome or constitutional mismatch repair deficiency syndrome[J].Hum Mutat,2016,37( 11) : 1162－1179. [12] Shia J, Schultz N, Kuk D, et al. Morphological characterization of colorectal cancers in the cancer genome atlas reveals distinct morphology- molecularassociations: clinical and biological implications[J].Mod Pathol, 2017, 30(4):599~609.
2019, Vol. 25 
冀公网安备13080202000677号